Dr Marie Spreckley

Who Dr Marie Spreckley is

Dr Marie Spreckley is a postdoctoral researcher at IMS Epidemiology, University of Cambridge, where her research focuses on obesity, nutrition, and incretin-based therapies. She is the programme manager for the five-year multidisciplinary Supporting Weight Management (SWiM) research programme in the Prevention of Diabetes and Related Metabolic Disorders in High-Risk Groups, which evaluates an acceptance-based guided self-help intervention for long-term weight management. She holds a PhD in Sustainable Weight Loss from Vrije University Amsterdam, an MSc in Obesity and Weight Management from the University of South Wales, and is a Registered Nutritionist (RNutr, Public Health) with the Association for Nutrition. She leads the AMPLIFY study, which explores lived experiences of incretin-based therapies across diverse and under-represented communities in the UK to inform clinical guidance and policy. She is regularly quoted in the UK press and by the Science Media Centre on the evidence base for GLP-1 receptor agonist therapies, their safety signals, and the need for nutritional support guidance for people using weight-loss medications.

References for this biography

1. 1.Dr Marie Spreckley – IMS Epidemiology, University of Cambridge (staff profile) — Current role, title, qualifications (PhD, RNutr, MSc, MBus, BA), SWiM programme manager role, teaching and committee memberships, postcode/address of organisation
2. 2.Dr Marie Spreckley – MRC Epidemiology Unit, University of Cambridge (staff profile) — Confirms role as programme manager, SWiM programme detail, MPhil teaching, PhD advising, Clare Hall affiliation, Race Equality Network and PdOC roles
3. 3.Marie Spreckley – Clare Hall, University of Cambridge (directory entry) — PhD from Vrije University Amsterdam, MSc from University of South Wales, RNutr status, editorial board membership of Cambridge Journal of Science & Policy
4. 4.Expert reaction to MHRA authorising orforglipron – Science Media Centre (August 2026) — Confirms current press-quoted role title; research focus on obesity, nutrition and incretin-based therapies; no industry funding declaration
5. 5.Expert reaction to reports of deaths after obesity drug use – Science Media Centre (August 2026) — Confirms Dr Spreckley as a regularly quoted UK press expert on GLP-1 therapy safety
6. 6.Lack of support for people on weight loss drugs – University of Cambridge news (January 2026) — Documents Spreckley leading the Obesity Reviews scoping review on GLP-1 nutritional guidance and her leadership of the AMPLIFY study
7. 7.AMPLIFY study – NIHR ARC East of England — Confirms Dr Spreckley as Principal Investigator of the AMPLIFY study, with NIHR funding
8. 8.Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss – International Journal of Obesity (November 2025) — Peer-reviewed publication confirming Spreckley's MRC Epidemiology Unit affiliation and research outputs

Notable achievements

• Led a systematic scoping review published in Obesity Reviews (January 2026) finding limited high-quality evidence on nutritional guidance for people using GLP-1 receptor agonist therapies, calling for urgent international nutrition guidelines. Source ↗
• Principal investigator of the AMPLIFY study (funded by NIHR via ARC East of England), a qualitative research project exploring lived experiences of incretin therapy use in under-represented communities across the UK. Source ↗
• Co-authored 'Bridging the nutrition guidance gap for GLP-1 receptor agonist therapy assisted weight loss: lessons from bariatric surgery', published in the International Journal of Obesity (November 2025). Source ↗
• Co-investigator on the SPROUT study (MRC Epidemiology Unit), exploring food insecurity, family systems, and responsive feeding practices during the first 1,000 days of child development. Source ↗

What Dr Marie Spreckley has said

• “However, the magnitude of these genetic effects is small in clinical terms. Importantly, non-genetic factors such as sex, drug type, dose and duration appear to explain a substantially larger proportion of variability.”

  obesity expert at the University of Cambridge · Public health & prevention · 10 Sept 2026 · Genetics may help explain why results from weight-loss jabs vary, say scientists ↗

• “Many people do not want to remain on injectable therapy indefinitely due to treatment burden, convenience, travel, storage requirements, cost or personal preference.”

  research programme manager at the University of Cambridge · Public health & prevention · 10 Sept 2026 · Daily pill can help people maintain weight loss after they come off jabs, trial shows ↗

• “The study found that GLP-1 receptor agonist use was associated with a higher relative risk of clinically recorded non-scarring hair loss than two alternative classes of diabetes medication.”

  weight management researcher at the University of Cambridge · Diabetes · 10 Sept 2026 · Increased risk of hair loss associated with GLP-1 weight-loss drugs, study finds ↗

• “Higher discontinuation due to adverse events, particularly gastrointestinal symptoms, is a key consideration and may have implications for tolerability and adherence in real-world settings.”

  MRC epidemiology unit at the University of Cambridge · Diabetes · 27 Aug 2026 · New GLP-1 pill helps patients lose up to 8% of body weight, trial shows ↗

• “The magnitude of weight loss observed is particularly notable. However, because this study compared retatrutide with placebo rather than semaglutide or tirzepatide, it is not possible to determine from this data whether retatrutide is superior, equivalent or inferior to currently available therapies.”

  specialist in prevention of diabetes and related metabolic disorders at IMS Epidemiology, University of Cambridge · Diabetes · 27 Aug 2026 · Triple-action diabetes jab shown to reduce blood sugar and body weight ↗

Where Dr Marie Spreckley has been quoted

1. Weight-loss drugs: A miracle treatment hindered by inequalityhealthcaretoday.com · 30 Sept 2026
2. Genetics may help explain why results from weight-loss jabs vary, say scientiststheguardian.com · 10 Sept 2026
3. Daily pill can help people maintain weight loss after they come off jabs, trial showstheguardian.com · 10 Sept 2026
4. Increased risk of hair loss associated with GLP-1 weight-loss drugs, study findspulsetoday.co.uk · 10 Sept 2026
5. New GLP-1 pill helps patients lose up to 8% of body weight, trial showstheguardian.com · 27 Aug 2026
6. Triple-action diabetes jab shown to reduce blood sugar and body weighttheguardian.com · 27 Aug 2026

Related media coverage

Recent UK press coverage of their topics — not necessarily citing them directly.

• Severe Type 1 Diabetes Onset Linked to Later ComplicationsEMJ
• Tazbentetol shows retinal neuroprotection potential in diabetic mouse modelDrug Target Review
• UK start-up takes on Americans with cheaper diabetes devicesThe Times

Contact & links

• Staff pagehttps://www.epi.ims.cam.ac.uk/people/marie-spreckley/
• Staff pagehttps://www.mrc-epid.cam.ac.uk/people/marie-spreckley/
• LinkedInhttps://www.linkedin.com/in/dr-marie-spreckley-570884a/
• Staff pagehttps://www.clarehall.cam.ac.uk/directory/marie-spreckley/

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.